Action signal — ⏳ Stage

Surfaced by the 2026-10-09 actions digest.

Action: ⏳ Stage (LOW) RSI: 25.9

Why this is in actions

Carried: argenx (US-listed ADS) fell about 13–14% on October 8 (Weiss Ratings; Mitrade) and lost its 200-day. Mitrade ties the drop to discontinuing the Phase 3 UNITY study in Sjögren's disease — aggregator-reported, no company release for it on file; the same day's company release reported positive Phase 2 celiac results (GlobeNewswire). Thesis still rated intact on the record

Trade Summary

Stub — ⏳ Stage means more research needed before action.

Sources

• Actions digest: 2026-10-09-actions-daily-digest
• Original row: | **ARGX** | $825.03 | reclaim of the 200-day ($851.97) | 25.9 | **-17.69%** | 2.5% | -3.2% | 2026-10-09 | carried (no October 9 scan) | ⏳ Stage | Carried: argenx (US-listed ADS) fell about 13–14% on
• Price truth: summaries